amiodarone

(redirected from Nexterone)
Also found in: Dictionary, Thesaurus.

amiodarone

 [ah-me´o-dah-rōn″]
a potassium channel blocking agent used orally or by intravenous infusion as the hydrochloride salt in treatment of ventricular arrhythmias.

amiodarone

/ami·o·da·rone/ (ah-me´o-dah-rōn″) a potassium channel blocking agent used as the hydrochloride salt in the treatment of ventricular arrhythmias.

amiodarone

(ə-mē′ō-də-rōn′, -rən)
n.
A vasodilator drug, C25H29I2NO3, used in its hydrochloride form to control ventricular and supraventricular arrhythmias and to manage angina pectoris.

amiodarone

Cordorone® Cardiology A class III agent that prolongs the duration of the action potential; amiodarone is used to treat refractory ventricular and supraventricular tachycardia, A Fib, conduction block Adverse effects Pulmonary fibrosis, which occurs in ±6% of Pts taking the drug, hypothyroidism, hyperthyroidism, deposits in cornea—causing photosensitivity and/or skin-blue/gray skin pigmentation, leukocytoclastic vasculitis, hepatitis, ↑ digitoxin levels, neurotoxicity, GI toxicity

amiodarone

A drug used to treat heart rhythm irregularities such as paroxysmal ATRIAL FIBRILLATION. There are numerous side effects. A brand name is Cordarone X.

amiodarone

drug used to maintain normal heart rhythm after reversion of atrial fibrillation; side-effects include altered thyroid function, vision impairment (especially during night driving) and skin photosensitivity

amiodarone

a drug that lengthens action potential duration and acts as a coronary vasodilator. Used in the treatment of ventricular and supraventricular arrhythmias.
References in periodicals archive ?
This level of sustaining investment has enabled Prism to pursue an aggressive licensing and rapid development model resulting in the successful approval of NEXTERONE.
The worldwide rights to NEXTERONE were licensed in early 2006 from CyDex Pharmaceuticals, Inc.
Cooper continued, "While this regulatory approval is for NEXTERONE supplied in vials and a prefilled syringe, the changes in the compatibility and stability profile of NEXTERONE, brought about by the removal of polysorbate 80 and benzyl alcohol, present the opportunity to formulate intravenous amiodarone for the first time in premixed, ready to use configurations.
Prism intends to submit a supplemental NDA for the premixed configurations which will form the focus of the commercial launch of NEXTERONE as a complete product line.
We intend to commercialize NEXTERONE ourselves in the US with partners that are well positioned in the hospital marketplace and will seek to license the ex-US worldwide rights," said Dr.
The FDA approval of NEXTERONE triggers a second $10M milestone payment from Paul Capital.
The development and approval of NEXTERONE has been Prism's greatest achievement," said Warren Cooper, CEO of Prism Pharmaceuticals.
NEXTERONE Premixed Injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.
Prism's success in advancing this new, premixed IV bag formulation of NEXTERONE demonstrates not only the role Captisol can play in the development of novel products for intravenous therapy in the hospital setting, but also the productivity of this longstanding licensing relationship.